Abstract
Previously, we demonstrated the involvement of Asn293 in helix VI of the human β2-adrenergic receptor in stereoselective agonist recognition and activation. In the present study, we have further explored the role of this residue by synthesizing derivatives of isoproterenol and clenbuterol, two β-adrenergic receptor agonists. We analyzed their efficacy and affinity on the wild-type and a mutant receptor (Asn293Leu). Each compound had similar efficacy (τ values) on both the wild-type and mutant receptor, although τ values varied considerably among the eight compounds studied. It appeared that one derivative of isoproterenol, but not of clenbuterol, showed a gain in affinity from the wild type to the mutant receptor. This derivative had a methyl substituent instead of the usual β-OH group in the aliphatic side chain of isoproterenol, compatible with the more lipophilic nature of the leucine side chain. Such a “gain of function” approach through a combination of synthetic chemistry with molecular biology, may be useful to enhance our insight into the precise atomic events that govern ligand-receptor interactions.
Footnotes
- Received February 23, 1999.
- Accepted July 22, 1999.
-
Send reprint requests to: Adriann P. IJzerman, Ph.D., Receptor Medical Chemistry, Leiden/Amsterdam Center for Drug Research, P.O. Box 9502, 2300RA Leiden, the Netherlands. E-mail:ijzerman{at}lacdr.leidenuniv.nl
-
This study was supported by grants from the European Community (programs EUROCEPTOR and InverseA).
- The American Society for Pharmacology and Experimental Therapeutics
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|